623577-59-3 Usage
General Description
4-Bromo-1-(4-fluoro-phenyl)-1H-imidazole is a chemical compound that consists of a bromine atom, a 1-(4-fluoro-phenyl) group, and an imidazole ring. It is commonly used in organic synthesis as a building block and intermediate for the production of pharmaceuticals, agrochemicals, and other fine chemicals. 4-BROMO-1-(4-FLUORO-PHENYL)-1H-IMIDAZOLE is known for its wide range of biological activities, including antiviral, antibacterial, and antifungal properties. It is also used as a reagent in various chemical reactions, such as Suzuki coupling and Sonogashira cross-coupling reactions. Additionally, 4-Bromo-1-(4-fluoro-phenyl)-1H-imidazole has potential applications in the development of new drugs and medical treatments due to its pharmacological properties.
Check Digit Verification of cas no
The CAS Registry Mumber 623577-59-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,2,3,5,7 and 7 respectively; the second part has 2 digits, 5 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 623577-59:
(8*6)+(7*2)+(6*3)+(5*5)+(4*7)+(3*7)+(2*5)+(1*9)=173
173 % 10 = 3
So 623577-59-3 is a valid CAS Registry Number.
623577-59-3Relevant articles and documents
Novel orally bioavailable γ-secretase inhibitors with excellent in vivo activity
Keown, Linda E.,Collins, Ian,Cooper, Laura C.,Harrison, Timothy,Madin, Andrew,Mistry, Jayesh,Reilly, Michael,Shaimi, Mohamed,Welch, Christopher J.,Clarke, Earl E.,Lewis, Huw D.,Wrigley, Jonathan D. J.,Best, Jonathan D.,Murray, Fraser,Shearman, Mark S.
supporting information; experimental part, p. 3441 - 3444 (2010/03/30)
The development of potent γ-secretase inhibitors having substituted heterocycles attached to a benzobicyclo[4.2.1]nonane core is described. This work led to the identification of [6S,9R,11R]-2′,3′,4′,5, 5′,6,7,8,9,10-decahydro-2-(5-(4-fluorophenyl)-1-methylpyrazol-3-yl) -5′-(2,2,2-trifluoroethyl)spiro[6,9-methanobenzocyclooctene-11, 3′-[1,2,5]thiadiazole] 1′,1′-dioxide (16), which has excellent in vitro potency (0.06 nM) and which reduced amyloid-β in APP-YAC mice with an ED50 of 1 mg/kg (po). 16 had a good pharmacokinetic profile in three preclinical species.